Skip to content

Investors

The institutional briefing.

AimwellBio is building the adversarial validation layer beneath AI-generated biopharma intelligence: four independent agents, one source-traced verdict. This page separates what is verifiable today from what is thesis, and says where the rest is shared.

Illustration: a person in a dark suit leaning over printed documents with a pencil.

Verified platform data

What the signal corpus contains today.

Signals indexed
4,500
Intelligence areas
9
Source types
4
Distinct signals
4,123
Last refresh
October 16, 2026

Operating data from the platform’s own signal manifest, on a scheduled refresh; not a live feed. See the Signals page. Revenue, customer counts and financial statements are not published here; they are shared under NDA.

Thesis · management view, not results

Why the verification layer matters.

  1. Trust is the barrierBiopharma executives name trust in AI output as a primary barrier to adoption, and general-purpose models can reproduce fabricated claims. A system that earns institutional trust addresses the barrier directly.
  2. The audit is the productFour independent agents review every brief and a documented verdict follows. The method is published as the Adversarial Validation Standard, so it can be examined by people who did not write it.
  3. Institutional memory compoundsEach correction, decision and review is retained, so the system’s value to an organization can deepen with use. This is an expectation, not a measured retention figure.
  4. Infrastructure, not a toolThe intent is to replace scattered, manual intelligence work with a single verified layer. It is early, and the thesis is untested at scale.

Access ladder · current public terms

How customers enter and expand.

TierPriceFor
ObserverFree, after approvalCredentialed professionals
Member$199 / monthAnalysts and clinicians running verdicts on a regular cadence
Signal$279 / monthPractitioners who need category monitoring
Shield$449 / month, by requestProfessionals who need protected decisions; dossier layer in activation
CommandBy arrangementTeams and departments, configured with review
Enterprise and sovereignBy arrangementMulti-department biopharma, institutional and sovereign health

Public list prices as shown on the pricing page. They are not revenue and say nothing about uptake.

Materials

Request current investor materials.

Full investor deck, financial model and growth roadmap are sent to qualified investors. An NDA is required for full financial materials. Our team verifies and responds, and materials are sent within 1 business day of qualification.

✓ Request received. Materials are sent within 1 business day.

Reading

Public documents.

  • The Biotech Intelligence ImperativeWhitepaper on the structural intelligence gap in biopharma.
    PDF
  • The Hallucination Liability CrisisThe case for containment infrastructure.
    PDF
  • The Decision System · Infrastructure BriefingSovereign-grade briefing on the threat, gap and asset framework.
    PDF
  • The Command Layer · Strategic BriefingStrategic briefing for sovereign and enterprise deployments.
    PDF
  • The Adversarial Validation StandardThe published methodology.
    Read
  • Security & complianceWhat is implemented, planned and not claimed.
    Read